TABLE 1.

Patients with BRAF-mutated neuroblastoma or VIP-D without BRAF mutation treated at Memorial Sloan Kettering Cancer Center from 2002–2019.

Patient	Age at Diagnosis of NB	Clinical Presentation	Stage	Mutations	Diarrhea	Highest VIP Level with Diarrhea
1	19 months old	Abdominal primary w/ metastases in liver, lung, bone, and bone marrow	4	Initial: BRAF p.V600E, MYCN Amplification Relapse: ALK p.F1174L, MYCN Amplification	After chemotherapy	>3200pg/mL
2	11 months old	Adrenal mass w/ metastases in liver and pleura	4	BRAF p.V600E, MYC-N amplification	After chemotherapy	1416pg/mL
3	4 months old	Adrenal mass w/ metastases in liver, soft tissue, and bone	4	Biopsy: MYCN Amplification Resection: ALK p.R1275Q, BRAF p.V600E, MYCN Amplification	None	N/A
4	11 months old	Abdominal primary w/ extension to spinal canal	3	BRAF p.V600E	None	N/A
5	17 months old	Abdominal primary	2	BRAF p.V600E	Before chemotherapy	486pg/mL
6	20 months old	Left neck mass	2	BRAF p.L597R	None	N/A
7	9 years old	Abdominal primary w/ metastases to bone and bone marrow	4	Initial: ALK p.R1275Q, MYCN Amplification, ATRX p.R250 Relapse: ALK p.R1275Q, BRAF p.G466E, ATRX p.R250	None	N/A
8	11 years old	Adrenal primary w/ metastases in liver and bone	4	BRAF p.G469A, ATRX p.R1739Hfs*8	None	N/A
9	13 years old	Adrenal primary w/ metastases in liver, bone, and bone marrow	4	BRAF F595L	None	N/A
10	21 months old	Abdominal primary w/ metastases in liver, bone marrow, bones	4	None	Before chemotherapy	>400 pg/mL
11	21 months old	Abdominal primary	3	None	Before chemotherapy	370 pg/mL
12	2 years old	Abdominal primary w/ metastases in soft tissue of neck	4	None	Before chemotherapy	142 pg/mL
13	2 years old	Abdominal primary w/ metastases in soft tissue, pleura, bone marrow	4	None	Before chemotherapy	184 pg/mL